INFLAMAÇÃO SUBCLÍNICA, OBESIDADE, DIABETES E DOENÇAS RELACIONADAS

Um estado de inflamação crônica subclínica, originado de uma dieta pró-inflamatória, do sedentarismo e de insultos intra-uterinos, entre outros fatores, está associado ao desenvolvimento do diabetes e de doenças cardiovasculares. Esse processo é mediado, em parte, pelo estresse oxidativo e por citocinas pró-inflamatórias, que interferem nos mecanismos de sinalização da insulina. A obesidade contribui para esse processo, uma vez que o tecido adiposo é hoje compreendido como um órgão secretor de produtos e mediadores pró-inflamatórios, como a interleucina-6 (IL-6) e o componente 3 do complemento (C3), e anti-inflamatórios, como a adiponectina. Outros fatores envolvidos são a alteração funcional do sistema nervoso autônomo e do sistema neuroendócrino, em resposta ao estresse. A insulina, em condições normais, apresenta efeitos antiinflamatórios. A resistência à insulina, uma vez presente, interromperia as ações inibitórias da insulina contra a inflamação, favorecendo também a manutenção do estado inflamatório crônico. Uma melhor compreensãodo papel do sistema imune inato na fisiopatologia da síndrome metabólica, do diabetes, da hipertensão e da doença cardiovascular, assim como das causas da ativação crônica desse sistema, deve levar a importantes avanços na predição, na prevenção e no manejo clínico dessas doenças.Unitermos: Diabetes melito, inflamação, obesidade, síndrome metabólica

Lesser than diabetes hyperglycemia in pregnancy is related to perinatal mortality: a cohort study in Brazil

Results: We ascertained 97 perinatal deaths (67 fetal and 31 early neonatal). Odds of dying increased according to glucose levels, statistically significantly so only for women delivering at gestational age ≥34 weeks (p < 0.05 for glycemia-gestational age interaction). ORs for a 1 standard deviation difference in glucose, when analyzed continuously, were for fasting 1.47 (95% CI 1.12, 1.92); 1-h 1.55 (95% CI 1.15, 2.07); and 2-h 1.53 (95% CI 1.15, 2.02). The adjusted OR for IADPSG criteria gestational diabetes was 2.21 (95% CI 1.15, 4.27); and for WHO criteria gestational diabetes, 3.10 (95% CI 1.39, 6.88). Conclusions: In settings of limited detection and treatment of gestational diabetes mellitus, women across a spectrum of lesser than diabetes hyperglycemia, experienced a continuous rise in perinatal death with increasing levels of glycemia after 34 weeks of pregnancy. Current GDM diagnostic criteria identified this increased risk of mortality

Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019 : a systematic analysis from the Global Burden of Disease Study 2019

Background Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco control efforts nationally and globally. Methods We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, providing more comprehensive estimates of the health effects of smoking than previously available. Findings Globally in 2019, 1·14 billion (95% uncertainty interval 1·13–1·16) individuals were current smokers, who consumed 7·41 trillion (7·11–7·74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had decreased significantly since 1990 among both males (27·5% [26·5–28·5] reduction) and females (37·7% [35·4–39·9] reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers from 0·99 billion (0·98–1·00) in 1990. Globally in 2019, smoking tobacco use accounted for 7·69 million (7·16–8·20) deaths and 200 million (185–214) disability-adjusted life-years, and was the leading risk factor for death among males (20·2% [19·3–21·1] of male deaths). 6·68 million [86·9%] of 7·69 million deaths attributable to smoking tobacco use were among current smokers. Interpretation In the absence of intervention, the annual toll of 7·69 million deaths and 200 million disability-adjusted life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large implementation gap remains for tobacco control. Countries have a clear and urgent opportunity to pass strong, evidencebased policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens

Diabetes mortality and trends before 25 years of age : an analysis of the Global Burden of Disease Study 2019

Background Diabetes, particularly type 1 diabetes, at younger ages can be a largely preventable cause of death with the correct health care and services. We aimed to evaluate diabetes mortality and trends at ages younger than 25 years globally using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Methods We used estimates of GBD 2019 to calculate international diabetes mortality at ages younger than 25 years in 1990 and 2019. Data sources for causes of death were obtained from vital registration systems, verbal autopsies, and other surveillance systems for 1990-2019. We estimated death rates for each location using the GBD Cause of Death Ensemble model. We analysed the association of age-standardised death rates per 100 000 population with the Socio-demographic Index (SDI) and a measure of universal health coverage (UHC) and described the variability within SDI quintiles. We present estimates with their 95% uncertainty intervals. Findings In 2019, 16 300 (95% uncertainty interval 14 200 to 18 900) global deaths due to diabetes (type 1 and 2 combined) occurred in people younger than 25 years and 73.7% (68.3 to 77.4) were classified as due to type 1 diabetes. The age-standardised death rate was 0.50 (0.44 to 0.58) per 100 000 population, and 15 900 (97.5%) of these deaths occurred in low to high-middle SDI countries. The rate was 0.13 (0.12 to 0.14) per 100 000 population in the high SDI quintile, 0.60 (0.51 to 0.70) per 100 000 population in the low-middle SDI quintile, and 0.71 (0.60 to 0.86) per 100 000 population in the low SDI quintile. Within SDI quintiles, we observed large variability in rates across countries, in part explained by the extent of UHC (r(2)=0.62). From 1990 to 2019, age-standardised death rates decreased globally by 17.0% (-28.4 to -2.9) for all diabetes, and by 21.0% (-33.0 to -5.9) when considering only type 1 diabetes. However, the low SDI quintile had the lowest decline for both all diabetes (-13.6% [-28.4 to 3.4]) and for type 1 diabetes (-13.6% [-29.3 to 8.9]). Interpretation Decreasing diabetes mortality at ages younger than 25 years remains an important challenge, especially in low and low-middle SDI countries. Inadequate diagnosis and treatment of diabetes is likely to be major contributor to these early deaths, highlighting the urgent need to provide better access to insulin and basic diabetes education and care. This mortality metric, derived from readily available and frequently updated GBD data, can help to monitor preventable diabetes-related deaths over time globally, aligned with the UN's Sustainable Development Targets, and serve as an indicator of the adequacy of basic diabetes care for type 1 and type 2 diabetes across nations. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.Peer reviewe

Validity of self-reported weight: a study of urban brazilian adults

Para avaliar a validade do peso auto-referido em inquéritos de prevalência de obesidade, o mesmo foi comparado com o peso medido de 659 adultos, residentes em Porto Alegre, RS, Brasil, em 1986-87. Ambos os pesos foram obtidos por entrevistador, na casa do participante, na mesma ocasião. A média das diferenças entre peso auto-referido e peso medido foi pequena (-0,06 +/-3,16 kg; média +/- desvio padrão) e a correlação entre eles alta (r=0,97). Sessenta e dois por cento dos participantes referiram seu peso com erro < 2 kg, 87% com erro menor do que 4 kg e 95% com erro < 6 kg. Indivíduos de baixo peso hiperestimaram seu peso, o oposto ocorrendo com indivíduos obesos (p; 30) por peso referido, foi de 10% e a por peso medido, de 11%. Concluindo, a validade do peso auto-referido é aceitável para inquéritos de prevalência realizados em contextos similares.In order to evaluate the validity of self-reported weight for use in obesity prevalence surveys, self-reported weight was compared to measured weight for 659 adults living in the Porto Alegre county, RS Brazil in 1986-87, both weights being obtained by a technician in the individual's home on the same visit. The mean difference between self-reported and measured weight was small (-0.06 +/- 3.16 kg; mean +/- standard deviation), and the correlation between reported and measured weight was high (r=0.97). Sixty-two percent of participants reported their weight with an error of < 2 kg, 87% with an error of < 4 kg, and 95% with an error of < 6 kg. Underweight individuals overestimated their weight, while obese individuals underestimated theirs (p; 30) by reported weight was 10%, by measured weight 11%. Thus, the validity of reported weight is acceptable for surveys of the prevalence of ponderosity in similar settings

An open - source mobile geospatial platform for promoting climate - smart livelihood - landscape systems in Fiji and Tonga

Communities in Fiji and Tonga rely on landscape services to support a variety of livelihoods. These communities are increasingly vulnerable to climate (e.g. increasing cyclone occurrence and intensity) and environmental (e.g. mining and deforestation) stressors. Within these landscape systems, accurate and timely monitoring of human-climate-environment interactions is important to inform landscape management, land use policies, and climate-smart sustainable development. Data collection and monitoring approaches exist to capture landscape-livelihood information such as surveys, participatory GIS (PGIS), and remote sensing. However, these monitoring approaches are challenged by data collection and management burdens, timely integration of databases and data streams, aligning system requirements with local needs, and socio-technical issues associated with low-resource development contexts. Such monitoring approaches only provide static representation of livelihood-landscape interactions failing to capture the dynamic nature of vulnerabilities, and benefit only a small user base. We present a prototype of a mobile, open-source geospatial tool being collaboratively developed with the Ministries of Agriculture in Fiji and Tonga and local stakeholders, to address the above shortcomings of PGIS and other environmental monitoring and data sharing approaches. The tool is being developed using open-source mobile GIS technologies following a formal ICT for Development (ICT4D) framework. We discuss the results for each component of the ICT4D framework which involves multiple landscape stakeholders across the two Small Island Developing States. Based on the ICT4D user requirements analysis, we produced a prototype open-source mobile geospatial data collection, analysis and sharing tool. New dynamic spatial data layers related to landscape use and climate were specifically developed for use in the tool. We present the functionality of the tool alongside the results of field-testing with stakeholders in Fiji and Tonga

Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies

An emerging body of evidence has implicated plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though findings have not always been consistent. We systematically reviewed epidemiological studies examining the association of PAI-1 with T2D. EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and 8 prospective) were included. In pooled random-effects analyses of prospective studies, a comparison of the top third vs. bottom third of baseline PAI-1 values generated a RR of T2D of 1.67 (95% CI 1.28-2.18) with moderate heterogeneity (I-2 = 38%). Additionally, of 47 cross-sectional comparisons, 34(72%) reported significantly elevated PAI-1 among diabetes cases versus controls, 2(4%) reported significantly elevated PAI-1 among controls, and 11(24%) reported null effects. Results from pooled analyses of prospective studies did not differ substantially by study design, length of follow-up, adjustment for various putative confounding factors, or study quality, and were robust to sensitivity analyses. Findings from this systematic review of the available epidemiological literature support a link between PAI-1 and T2D, independent of established diabetes risk factors. Given the moderate size of the association and heterogeneity across studies, future prospective studies are warranted